Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rim, Chai Hong | - |
dc.contributor.author | Shin, In-Soo | - |
dc.contributor.author | Park, Sunmin | - |
dc.contributor.author | Lee, Hye Yoon | - |
dc.date.accessioned | 2021-08-30T04:01:25Z | - |
dc.date.available | 2021-08-30T04:01:25Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2021-01-21 | - |
dc.identifier.issn | 2397-768X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/50081 | - |
dc.description.abstract | We conducted a meta-analysis of articles published in PubMed, MEDLINE, EMBASE, and Cochrane library to investigate the effectiveness of local consolidative therapy (LCT) against oligometastases. Data from randomized controlled trials (RCTs), balanced studies, and all studies combined were analyzed in a hierarchical manner. Pooled analyses of 31 studies (including seven randomized trials) investigating the effectiveness of LCT on overall survival revealed odds ratios of 3.04, 2.56, and 1.41 for all studies, balanced studies, and RCTs, respectively (all p < 0.05). The benefit of LCT was more prominent in patients with non-small cell lung and colorectal cancers than in those with prostate and small cell lung cancers. Moreover, the benefit of LCT was smaller in patients with high metastatic burdens (p = 0.054). In four of 12 studies with available information, additional grade >= 3 toxicities due to LCTs were reported. Overall, LCT is beneficial for patients with oligometastases, although such benefits are less evident in RCTs than in observational studies. Appropriate LCTs should be carefully selected considering their feasibility, disease type, and metastatic burden. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE RESEARCH | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | COLORECTAL-CARCINOMA METASTASES | - |
dc.subject | STEREOTACTIC BODY RADIOTHERAPY | - |
dc.subject | PHASE-II | - |
dc.subject | HEPATOCELLULAR-CARCINOMA | - |
dc.subject | ABLATIVE TREATMENT | - |
dc.subject | HEPATIC RESECTION | - |
dc.subject | THERAPY | - |
dc.subject | DISEASE | - |
dc.subject | SCORE | - |
dc.title | Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rim, Chai Hong | - |
dc.identifier.doi | 10.1038/s41698-020-00141-4 | - |
dc.identifier.scopusid | 2-s2.0-85114306570 | - |
dc.identifier.wosid | 000613012800002 | - |
dc.identifier.bibliographicCitation | NPJ PRECISION ONCOLOGY, v.5, no.1 | - |
dc.relation.isPartOf | NPJ PRECISION ONCOLOGY | - |
dc.citation.title | NPJ PRECISION ONCOLOGY | - |
dc.citation.volume | 5 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | COLORECTAL-CARCINOMA METASTASES | - |
dc.subject.keywordPlus | STEREOTACTIC BODY RADIOTHERAPY | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | ABLATIVE TREATMENT | - |
dc.subject.keywordPlus | HEPATIC RESECTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | SCORE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.